International Federation of Gynecology and Obstetrics staging classification for cancer of the ovary, fallopian tube, and peritoneum; Estimation of survival in patients with node-positive epithelial ovarian cancer

International Journal of Gynecological Cancer

Volumn 25, Issue 1, 2015, Pages 49-54

  Pereira, Augusto ^a   Pérez Medina, Tirso ^b   Magrina, Javier F ^c   Magtibay, Paul M ^c   Rodríguez Tapia, Ana ^d   Peregrin, Irene ^c   Mendizabal, Elsa ^a   Ortiz Quintana, Luís ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c MAYO CLINIC   (United States)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

5 year overall survival; FIGO staging classification; Ovarian cancer

Indexed keywords

ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS STAGING CLASSIFICATION; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OVARY CARCINOMA; OVERALL SURVIVAL; PERITONEUM CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; UTERINE TUBE TUMOR; CANCER GRADING; CYSTADENOCARCINOMA, SEROUS; FALLOPIAN TUBE NEOPLASMS; FOLLOW UP; INTERNATIONAL COOPERATION; LYMPH NODE; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PATHOLOGY; PELVIC NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; SECONDARY; SURVIVAL RATE; TUMOR INVASION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, SEROUS; CYTOREDUCTION SURGICAL PROCEDURES; FALLOPIAN TUBE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL AGENCIES; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PELVIC NEOPLASMS; PERITONEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; YOUNG ADULT;

EID: 84927714904     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000316     Document Type: Article

References (12)

1. Staging Announcement: FIGO Cancer Committee. Gynecol Oncol. 1986;25:383.
2. Prat J. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol Obstet. 2014;124:1-5.
3. American Cancer Society. Ovarian Cancer Overview. Available at: http://www.cancer.org/cancer/ovariancancer/overviewguide/ovarian-cancer-overview-survival.
4. Pereira A, Magrina JF, Rey V, et al. Pelvic and aortic lymph node metastasis in epithelial ovarian cancer. Gynecol Oncol. 2007;105:604-608.
5. Pereira A, Magrina JF, Magtibay PM, et al. The impact of peritoneal metastases in epithelial ovarian cancer with positive nodes. Int J Gynecol Cancer. 2011;21:1375-1379.
6. Pereira A, Pérez-Medina T, Magrina JF, et al. The role of lymphadenectomy in node-positive epithelial ovarian cancer. Int J Gynecol Cancer. 2012;22:987-992.
7. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
8. Pereira A, Pérez-Medina T, Magrina JF, et al. The impact of pelvic retroperitoneal invasion and distant nodal metastases in epithelial ovarian cáncer. Surg Oncol. 2014;23:40-44.
9. Bakkar R, Gershenson D, Fox P, et al. Stage IIIC ovarian/peritoneal serous carcinoma: A heterogeneous group of patients with different prognoses. Int J Gynecol Pathol. 2014;33:302-308.
10. Singh N, Gilks CB, Wilkinson N, et al. Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: A proposal. Histopathology. 2014;65:149-154.
11. Hamilton CA, Miller A, Miller C, et al. The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: A Gynecologic Oncology Group study. Gynecol Oncol. 2011;122:521-526.
12. Martinez A, Pomel C, Mery E, et al. Celiac lymph node resection and porta hepatis disease resection in advanced or recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol. 2011;121:258-263.